ArticleCureus2025
A Case of Slowly Progressive Type 1 Diabetes Mellitus (SPIDDM, Probable) Successfully Managed With Oral Semaglutide for Glycemic Control and Weight Management Accompanied by Changes in Eating Behavior.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a standard treatment for slowly progressive type 1 diabetes mellitus (SPIDDM), a condition akin to latent autoimmune diabetes in adults (LADA) or latent autoimmune diabetes in the young (LADY), and a term primarily used in Japan, remains to be fully established. However, these agents show potential as a therapeutic option. We report a case of a 23-year-old Japanese woman who had SPIDDM (probable) since the age of 19 and had poor glycemic and weight control despite treatment with insulin, dapagliflozin, and metformin. Following the initiation of oral semaglutide (a GLP-1 RA), significant improvements in glycemic levels and weight were observed, enabling the discontinuation of insulin. Notably, beneficial changes in her eating behavior were also evident after oral semaglutide administration. This case suggests that GLP-1 RAs are a beneficial therapeutic option for glucose and weight management in patients with SPIDDM (probable), particularly when accompanied by favorable alterations in eating behavior, thus warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.